BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Koren DE, Zuckerman A, Teply R, Nabulsi NA, Lee TA, Martin MT. Expanding Hepatitis C Virus Care and Cure: National Experience Using a Clinical Pharmacist-Driven Model. Open Forum Infect Dis. 2019;6. [PMID: 31363775 DOI: 10.1093/ofid/ofz316] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Tsui JI, Barry MP, Austin EJ, Sweek EW, Tung E, Hansen RN, Ninburg M, Scott JD, Glick SN, Williams EC. 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs. Addict Sci Clin Pract 2021;16:52. [PMID: 34384494 DOI: 10.1186/s13722-021-00260-8] [Reference Citation Analysis]
2 Scaglione V, Mazzitelli M, Costa C, Pisani V, Greco G, Serapide F, Lionello R, La Gamba V, Marascio N, Trecarichi EM, Torti C. Virological and Clinical Outcome of DAA Containing Regimens in a Cohort of Patients in Calabria Region (Southern Italy). Medicina (Kaunas) 2020;56:E101. [PMID: 32121135 DOI: 10.3390/medicina56030101] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
3 Anguiano RH, Zuckerman AD, Hall E, Diamantides E, Kumor L, Duckworth DL, Peter M, Sorgen PJ, Nathanson A, Kandah H, Dura J, Campbell U. Comparison of provider satisfaction with specialty pharmacy services in integrated health-system and external practice models: A multisite survey. American Journal of Health-System Pharmacy 2021;78:962-71. [DOI: 10.1093/ajhp/zxab079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Parihar V, Katz L, Siyam MA, Rogers A, Patterson L, Zacharias R. Mandatory pharmacist-led education session for patients seeking medical cannabis. Pharm Pract (Granada) 2020;18:2088. [PMID: 33343771 DOI: 10.18549/PharmPract.2020.4.2088] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Ulrich IP, Lugo B, Hughes P, Doucette L, Creith BB, Flanagan S, Gilmer B. Access to clinical pharmacy services in a pharmacist-physician covisit model. Res Social Adm Pharm 2021;17:1321-6. [PMID: 33153913 DOI: 10.1016/j.sapharm.2020.10.002] [Reference Citation Analysis]
6 Behnke C, Nissim O, Simerlein W, Beeker K, Tarleton JL, Lazenby GB. Quality improvement to evaluate and provide treatment for chronic hepatitis C postpartum. J Am Pharm Assoc (2003) 2021:S1544-3191(21)00553-7. [PMID: 34975005 DOI: 10.1016/j.japh.2021.12.006] [Reference Citation Analysis]
7 Yang A, Zachary D, Giang J. Impact of a Nurse Care Coordinator Supporting a Clinical Pharmacist Practitioner in Further Managing HCV-Infected Patients. Gastroenterol Nurs 2021;44:E11-7. [PMID: 33464766 DOI: 10.1097/SGA.0000000000000578] [Reference Citation Analysis]
8 Hasan F, Alfadhli A, Al-Gharabally A, Alkhaldi M, Colombo M, Lazarus JV. Accelerating the elimination of hepatitis C in Kuwait: An expert opinion. World J Gastroenterol 2020; 26(30): 4415-4427 [PMID: 32874054 DOI: 10.3748/wjg.v26.i30.4415] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Wade AJ. Can community pharmacists treat hepatitis C virus? Lancet Gastroenterol Hepatol 2020;5:790-1. [PMID: 32526211 DOI: 10.1016/S2468-1253(20)30184-9] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Loucks J, Zuckerman AD, Berni A, Saulles A, Thomas G, Alonzo A. Proportion of days covered as a measure of medication adherence. Am J Health Syst Pharm 2021:zxab392. [PMID: 34637496 DOI: 10.1093/ajhp/zxab392] [Reference Citation Analysis]
11 Fanizza FA, Loucks J, Berni A, Shah M, Grauer D, Daniel S. Patient Access to Hepatitis C Treatment After Incorporation of Pharmacists in a Hepatology Clinic. Hosp Pharm. [DOI: 10.1177/00185787211037540] [Reference Citation Analysis]
12 Martin MT, Waring N, Forrest J, Nazari JL, Abdelaziz AI, Lee TA. Sustained Virologic Response Rates Before and After Removal of Sobriety Restriction for Hepatitis C Virus Treatment Access. Public Health Rep. [DOI: 10.1177/00333549221099323] [Reference Citation Analysis]
13 Hayward KL, Weersink RA. Improving Medication-Related Outcomes in Chronic Liver Disease. Hepatol Commun 2020;4:1562-77. [PMID: 33163829 DOI: 10.1002/hep4.1612] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Hanna J, Sufian J, Suh JS, Jimenez HR. Hepatitis C virus micro-elimination within a clinic for people with HIV: challenges in the home stretch. HIV Med 2022. [PMID: 35150183 DOI: 10.1111/hiv.13241] [Reference Citation Analysis]
15 Nabulsi NA, Martin MT, Sharp LK, Koren DE, Teply R, Zuckerman A, Lee TA. Predicting Treatment Failure for Initiators of Hepatitis C Virus Treatment in the era of Direct-Acting Antiviral Therapy. Front Pharmacol 2020;11:551500. [PMID: 33364936 DOI: 10.3389/fphar.2020.551500] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Livezey S, Shah NB, McCormick R, DeClercq J, Choi L, Zuckerman AD. Specialty pharmacist integration into an outpatient neurology clinic improves pimavanserin access. Ment Health Clin 2021;11:187-93. [PMID: 34026394 DOI: 10.9740/mhc.2021.05.187] [Reference Citation Analysis]